English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduPhysician-scientists from Cedars-Sinai Cancer are available for comment on research being presented throughout the San Antonio Breast Cancer Symposium, taking place Dec. 6-10.
Tag: San Antonio Breast Cancer Symposium
Mindfulness meditation, survivorship classes reduce symptoms of depression in younger breast cancer survivors
New UCLA-led research shows that behavioral interventions — mindfulness meditation and survivorship education classes — are effective in reducing depressive symptoms in younger breast cancer survivors, who often experience the highest levels of depression, stress and fatigue that can persist for as long as a decade after their diagnosis.
Rutgers Cancer Institute of New Jersey Experts Available for Comment on General Breast Cancer Topics During Virtual San Antonio Breast Cancer Symposium (SABCS)
New Brunswick, N.J., December 7, 2020 – The San Antonio Breast Cancer Symposium (SABCS) provides an opportunity for basic, translational and clinical cancer research professionals to experience and discuss the most current research and advances in the field of breast…
Mayo Clinic researchers present findings at the 2019 San Antonio Breast Cancer Symposium
Mayo Clinic researchers will present findings at the San Antonio Breast Cancer Symposium Dec. 10–14 in San Antonio.
Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer
Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses image-guided breast biopsies to reliably predict residual disease in breast cancer patients and that potentially identifies exceptional responders who may not require surgery.
Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.
Analysis of Different Treatment Strategies for Non-Invasive Breast Cancer Shows Radiation Treatment Alone is Cost-Effective
Rutgers Cancer Institute of New Jersey investigators evaluated all treatment strategies for both standard-risk and good-risk ductal carcinoma in-situ and found the most commonly recommended combination treatment for DCIS represents low-value care, while radiation therapy alone was cost-effective.
Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.